bioAffinity Technologies, Inc. announced a significant increase in revenue and unit sales for its CyPath® Lung diagnostic test, with a 87% revenue growth and a 99% increase in tests performed compared to 2024. The company aims to expand its market presence in 2026.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.